Ariad loses $65M patent appeal against Eli Lilly
Monday’s decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly’s osteoporosis
drug Evista and sepsis medicine Xigris.
Life Science & Biotech
Articles
Lilly buys right to underarm lotion for low sex drive
Eli Lilly & Co., the maker of the impotence pill Cialis, bought exclusive rights from Australia’s Acrux Ltd. to
an underarm testosterone lotion called Axiron for men with limited sex drive due to low levels of the hormone.
FDA says ‘not yet’ on Lilly’s once-weekly Byetta
Regulators won’t require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling,
manufacturing
processes.
Eli Lilly to buy European rights to Pfizer animal products
The acquisition will benefit Elanco, Lilly’s animal health division in Greenfield, which has become increasingly important
to Lilly as it braces for patent-protection losses.
Dow AgroSciences considered expansion elsewhere
Agricultural biotech firm hired a site-selection consultant and considered other cities around the world for its $340 million
expansion.
Dow Agro plans $340M expansion, 577 new jobs
The investment will greatly expand the company’s research and development capacity and is a major win for the Indiana
life sciences industry. Dow AgroSciences expects most of the positions to pay between $65,000 and $95,000 annually.
Cornelius to retire as Bristol-Myers Squibb CEO
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
Dow Agro plans ‘major’ expansion announcement
Local Dow Chemical subsidiary expects to launch five new biotech products by 2012.
Lilly to shift more employees to Covance
Greenfield Labs operation expects to add 17 Eli Lilly and Co. workers after taking over staff of 264 in 2008 acquisition.
Indiana companies that serve pharmaceutical industry grew in 2009
The firms continued to grow over the last year but face increasing challenges, according to a new report by Indianapolis-based
life sciences trade group BioCrossroads.
Vortek Surgical moving HQ to Brownsburg, adding 60 jobs
Indianapolis-based Vortek Surgical LLC will relocate to Brownsburg, expanding its headquarters, manufacturing and distribution
operations and creating more than 60 jobs in the next three years.
Bioanalytical Systems reports quarterly loss
Bioanalytical Systems Inc., a West Lafayette-based life sciences contract research firm, on Wednesday reported a loss of $1.4
million for its fiscal first quarter.
Dow Agro CEO says pipeline of products strong
Dow AgroSciences CEO Antonio Galindez told investors Wednesday morning that the company plans to launch five products
by 2013 that could increase annual revenue by $800 million.
Report: State’s pharmaceutical contractors continue to grow
A report set to be released Wednesday by local life sciences industry group BioCrossroads says Indiana companies providing
contract pharmaceutical research and manufacturing services are weathering the economic downturn and are growing.
Underrated entrepreneurs
The Indianapolis area is home to myriad unsung entrepreneurs who run interesting companies, make money and create good jobs.
Here are some of them.
Health care venture capital swoons in Indy, holds steady statewide
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009.
Indy without Lilly, the 500?
An Indiana University prof thinks Indianapolis should anticipate a future without Indianapolis Motor Speedway, and a potentially
reduced Eli Lilly and Co.
Health firms still attracting venture capital
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009. That trend hit Indianapolis,
but the rest of the state actually saw an increase.
Dow AgroSciences profit falls despite revenue increase
Indianapolis-based Dow AgroSciences said Tuesday it posted a profit of $69 million in the fourth quarter, down 19 percent
from the prior year because of increased research and development spending and higher administrative expenses. Revenue was
up 17 percent.
City of Greenwood might fund launch of insulin maker
Greenwood-based Zimmerman Biotechnologies LLC hopes to become the first company in the United States to make generic insulin,
a long-awaited development in diabetes treatment. The Greenwood Common Council on Feb. 1 will consider an $8.4 million deal
that would finance construction of an insulin factory, as well as help Zimmerman with FDA-approval and equipment expenses.